Ticagrelor-14s-count001-b (Ticagrelor 14s Count001 B)
Ticagrelor Tablet, Film Coated
Product Images NDC 67877-522
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 22 technical images submitted to the FDA as part of the official labeling for Ticagrelor (NDC 67877-522). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Ascend Laboratories, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Ticagrelor 500 Label (Ticagrelor 500 3b)
Ticagrelor-deboss (Ticagrelor Deboss)
Ticagrelor-fig1 (Ticagrelor Fig1)
Ticagrelor-fig10 (Ticagrelor Fig10)
This text contains data related to the usage of Clopidogrel, a medication used to prevent heart attacks and strokes. The data includes information on patients with events, survival rates at 12 months, hazard ratio, and p-value. Additionally, it provides a graph showing the number of patients at risk over the course of 360 days.*
Ticagrelor-fig11 (Ticagrelor Fig11)
The provided text appears to be a set of detailed statistical data and percentages related to characteristics, treatment effects, and demographics from a research study. The data includes information on variables such as geographic region, planned treatment approach, patient demographics (age, sex, race), medical history (diabetes, prior TIA/stroke), treatments received, and outcomes analyzed. The text also shows numerical values and confidence intervals for different treatment groups, comparing ticagrelor and clopidogrel. The study seems to have evaluated the effectiveness of these treatments based on various factors.*
Ticagrelor-fig12 (Ticagrelor Fig12)
Ticagrelor-fig13 (Ticagrelor Fig13)
Ticagrelor-fig14 (Ticagrelor Fig14)
Characteristics HR (95% CI) for different groups such as age, weight, geographic region, history of PCI, type of stent, smoking status, diabetes mellitus, and more are provided in the data. The data analysis also includes the overall treatment effect and the primary endpoint for the study. This detailed information can aid in understanding the impact of various factors on the treatment outcomes evaluated in the study.*
Ticagrelor-fig15 (Ticagrelor Fig15)
This dataset seems to present the results of a clinical trial involving ticagrelor and placebo over a period of months. The cumulative percentage at different time points is shown for each group, indicating the number of patients at risk. It appears that the study had a duration of up to 54 months.*
Ticagrelor-fig16 (Ticagrelor Fig16)
This text provides valuable data on the evaluation of ticagrelor compared to placebo in various patient demographics and clinical characteristics. It includes information on the effects of ticagrelor versus placebo across different age groups, gender, race, body mass index, geographic regions, aspirin dose, HbA1c levels, eGFR, insulin use, history of angina, coronary artery disease, PCI, CABG, smoking status, and duration of diabetes. The results indicate the efficacy of ticagrelor in different subgroups of patients, highlighting differences in outcomes and risk factors. This information can be useful for healthcare professionals and researchers in understanding the impact and effectiveness of ticagrelor relative to placebo in diverse patient populations.*
Ticagrelor-fig17 (Ticagrelor Fig17)
Ticagrelor-fig18 (Ticagrelor Fig18)
Ticagrelor-fig2 (Ticagrelor Fig2)
Ticagrelor-fig3-a (Ticagrelor Fig3 A)
Ticagrelor-fig4 (Ticagrelor Fig4)
This is a description of a clinical trial evaluating the efficacy of Ticagrelor 90 mg compared to placebo. The data shows the number of events, cumulative percentage, and days from randomization. Ticagrelor had a cumulative percentage of 0.5%, while placebo had a percentage of 0.1%. The graph displays a comparison over time.*
Ticagrelor-fig5 (Ticagrelor Fig5)
Ticagrelor-fig6 (Ticagrelor Fig6)
Ticagrelor-fig7 (Ticagrelor Fig7)
This text provides information on the mean effect and 90% confidence interval for intrinsic factors influencing the recommendation of Ticagrelor AR-C124910XX. It includes factors such as age, gender, ethnicity, renal function, end-stage renal disease, and hepatic impairment, along with dosage adjustment recommendations for each factor.*
Ticagrelor-fig8 (Ticagrelor Fig8)
This text provides information on Ticagrelor interactions with various drugs categorized based on their effects and recommendations for use. It includes details on strong, moderate, and potent CYP3A4 inhibitors, CYP3A4 inducers, P-gP and CYP3A inhibitors, and specific dosing recommendations and adjustments. The text also mentions the importance of avoiding concomitant use of certain drugs and potential dose adjustments. Additionally, there is reference to specific sections for more detailed information.*
Ticagrelor-fig9 (Ticagrelor Fig9)
This text appears to be a summary of interactions between Ticagrelor and different drugs at varying doses. It includes information on the mean effect and recommendations for interactions with drugs such as Simvastatin, Atorvastatin, Levonorgestrel, Ethinyl Estradiol, Tolbutamide, Digoxin, and Cyclosporine. The text also mentions dose adjustments and specific drug doses for optimal interactions. PK, Cmax, and AUC parameters are also noted in the text.*
Ticagrelor-struct (Ticagrelor Struct)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
